Roche's trial, targeting 330 patients globally and due to start in
early April, follows similar efforts by China in trying out the
decade old anti-inflammation drug to help patients whose bodies are
having a severe reaction after infection with the virus.
Sanofi and Regeneron are also testing an arthritis medicine, Kevzara,
that works similarly to Actemra after data from China suggested it
may help patients suffering from an overactive inflammatory response
in the lungs.
(Reporting by John Miller, editing by John Revill)
[© 2020 Thomson Reuters. All rights
Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.